Vyome Holdings, Inc. - Common Stock (HIND)

Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, on April 21, 2026.

Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (“MFW”) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego.

Vyome Holdings, Inc., (“Vyome”) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq.

Livechain, Inc. (“Livechain”) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, d/b/a, Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company.

Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, a Springer-Nature journal1.

Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program.

Vyome Holdings, Inc. (“Vyome” or the “Company”) (Nasdaq: HIND) announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds (“MFW”). The Company accomplished this funding need using its existing At-The-Market (“ATM”) facility.

Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis commissioned by Vyome and conducted by Destum Partners, Inc. (“Destum Partners”), a reputed life sciences strategy and transaction advisory firm.

Vyome Holdings, Inc. (“Vyome’) (Nasdaq: HIND) announced its subsidiary, LiveChain, Inc. (“Livechain” or “LICH”) (OTC Markets: LICH) has executed a binding letter of intent (“LOI”) with Remus Capital, a leading AI-focused venture capital firm, that will put LiveChain in control of the Humanyze brand, intellectual property, and other know-how of Sociometric Solutions, Inc. DBA Humanyze (“Humanyze”), a rapidly emerging AI-enabled human resources data and analytics company.

Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (“MFW”). VT-1953, a first-in-class immunomodulator for this indication, achieved both its primary and secondary endpoints. With this result, Vyome plans to advance to Phase III pivotal trial, seek FDA approval, and enter the $1B potential addressable market as the only anticipated approved solution for malignant fungating wounds.

Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome’s lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026.

Vyome Holdings, Inc., (“Vyome”) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the US–India innovation corridor, today announced its financial results and a series of corporate and clinical milestones following its successful listing on Nasdaq.

Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) announced it held its annual shareholder meeting on October 28, 2025.